logo
logo

Novalis Biotech Closes €25 Million Biotech Acceleration Fund

Jun 30, 2021•about 4 years ago

Amount Raised

€25 Million

Ghent

Description

Novalis Biotech, an early-stage venture capital investor in technologies aimed at revolutionizing healthcare, announced today the closing of its €25 million second fund, the Novalis Biotech Acceleration Fund. Both new and returning investors have participated in the fundraising. The second fund investor base includes institutional investors, such as Participatie Maatschappij Vlaanderen (PMV), family offices, as well as HNWIs.

Company Information

Company

Novalis Biotech Acceleration

Location

Ghent, East Flanders, Belgium

About

Novalis Biotech (Ghent, Belgium) is an early-stage venture capital investor in technologies that revolutionize healthcare. The company’s core competence lies in digitalization in the life sciences with a focus on capital light “enabling technologies” such as bioinformatics, AI, genomics, personalized medicine, research or manufacturing tools and diagnostics. For more information, please visit www.noval.is.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech